Ayurveda needs stronger research, scientific validation, and safety monitoring to build a credible pipeline from traditional knowledge to market-ready products.
Regulatory watch intensifies as the EU and FDA clear new treatments while India rewires sterile-drug licensing, digital regulation and CDSCO capacity.
This Week in Biosimilars highlights oncology taking the Lead in India as Dr. Reddy’s enters the nivolumab market and competition expands patient access.
Today’s pharma deals map the full innovation cycle, spanning oral biologics discovery, vaccine market access, and gene-therapy regulatory approval.
India’s CDMO boom is accelerating as global pharma moves beyond China+1, seeking advanced capabilities, regulatory strength and long-term partnerships.
Pharma faces a pipeline paradox today as companies chase AI-powered R&D while trial failures, IP battles, and quality gaps widen.
Alkem’s NeuCeno brings cenobamate to Indian patients, offering a once-daily anti-seizure treatment option for adults with partial-onset seizures.
FDA Today brings fresh developments across drug access, approvals and new pathways, spanning oncology, respiratory care and emerging psychedelic therapies.
Pharma’s rough patch deepens as fines, clinical failures and market fallout put safety, efficacy and investor confidence under pressure.
India’s biopharma sector is gaining regulatory strength as Biopharma SHAKTI and IPC’s quality push support biologics and biosimilars growth.
.jpg)
, CDSCO.jpg)
